好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurocysticercosis in Qatar
Infectious Disease
P5 - Poster Session 5 (5:30 PM-6:30 PM)
4-032
To describe the occurrence and features of Neurocystircercosis (NCC) in Qatar.
Qatar is a small country in the Arabian Peninsula, with a mixed population of natives and expats. NCC is not endemic to the region, but clinical practice suggests its occurrence in increasing numbers.
A database was created to summarize information retrospectively collected on patients with NCC seen through the national health system (HMC) between 2013 and 2018. We identified demographic and disease-related variables (symptomatology, radiological findings, treatment and outcome) for all patients.

This analysis included information from 260 patients. Ninety-seven percent are men, and 99.2% are nationals of NCC endemic countries, mainly from Nepal (58.5%) and India (35.0%).

Seizures were the most common presentation (81.2%), with generalized tonic-clonic seizures being the most common type (61.5%). Headaches were present in 20.4% of the cases. On imaging, 47.9% had only one NCC lesion, and 55.8% of cases included pathology at the calcified stage. The granulonodular, colloidal and vesicular stages were seen respectively in 34, 29 and six percent of cases. Lesions were almost always parenchymal in location (99.6%), most frequently in the frontal lobe (58.8%). Albendazole was administered in 60.0% of subjects, and dexamethasone in 56.5%. Phenytoin was the most frequently prescribed anti-seizure medication (58.1%), followed by levetiracetam (18.1%). When follow up information was available, clinical improvement was noted in 85.9% of this subset.

To our knowledge, this is the first detailed NCC case-series from Qatar and the region. Massive immigration from Southeast Asia is making this diagnosis all too familiar. NCC is now a significant etiology of epilepsy in Qatar, often with a good outcome regarding seizure control. NCC with single lesion seems to be overrepresented in our cohort.
Authors/Disclosures
Yanal R. Shaheen, MD (SUNY Downstate Medical Center)
PRESENTER
Dr. Shaheen has nothing to disclose.
Fatima Al-Maadid, MD No disclosure on file
No disclosure on file
Gayane R. Melikyan, MD, FAAN (Hamad Medical Coorporation) Dr. Melikyan has nothing to disclose.
Boulenouar Mesraoua, MD, FAAN (Hamad Medical Corporation) Dr. Mesraoua has nothing to disclose.
Dirk T. Deleu, MD, PhD, FRCP, FAAN (Hamad Medical Corporation/Weill Cornell MC) Dr. Deleu has nothing to disclose.
Hassan Jassim Al Hail, MD, FAAN (HMC) Dr. Al Hail has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Naim I. Haddad, MD, FAAN (WCM-Q) Dr. Haddad has nothing to disclose.